Boehringer Ingelheim GmbH Corporate Head Office Corporate Communications represented by the Board of Managing Directors: Prof. Dr Dr Andreas Barner, Hubertus von Baumbach, Prof. h.c. Dr Wolfram Carius, Engelbert Tjeenk Willink 55216 Ingelheim, Germany
Telephone: +49-6132-77-0 Fax: +49-6132-77-3000 For queries please click here
District Court: Mainz, HRB 21005 Identification number for turnover tax: DE 81 11 37 994
Source for healthcare professionals: www.inoncology.com * Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.